Literature DB >> 20873969

Interferon-β treatment associated with a biochemical profile suggestive of acromegaly. A case report of a patient treated for multiple sclerosis.

Mikkel Andreassen1, Jan Frystyk, Karen K Miller, Lars Ø Kristensen.   

Abstract

We describe a 34-year-old female treated with IFN-β for 8 years with a biochemical profile suggestive of acromegaly. The patient presented with elevated serum insulin-like growth factor-I (IGF-I) and insufficient suppression of growth hormone (GH) during oral glucose tolerance test (OGTT). There were no clinical features of acromegaly. A 5-day profile showed higher GH levels on the 3 days following IFN-β injections. Total and bioactive IGF-I were also elevated but did not fluctuate. Four weeks off IFN-β normalized suppression of GH during OGTT but did not reduce serum IGF-I or bioactive IGF-I. In conclusion, IFN-β treatment mimicked acromegaly biochemically. The changes were partially reversible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20873969      PMCID: PMC3668555          DOI: 10.3109/00365513.2010.521256

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  15 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

2.  Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis.

Authors:  Florian Then Bergh; Tania Kümpfel; Alexander Yassouridis; Christian Lechner; Florian Holsboer; Claudia Trenkwalder
Journal:  Clin Endocrinol (Oxf)       Date:  2007-02       Impact factor: 3.478

3.  Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration.

Authors:  N Caraccio; A Dardano; F Manfredonia; L Manca; L Pasquali; A Iudice; L Murri; E Ferrannini; F Monzani
Journal:  J Clin Endocrinol Metab       Date:  2005-04-05       Impact factor: 5.958

4.  Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C.

Authors:  P Del Monte; D Bernasconi; V De Conca; M Randazzo; M Meozzi; B Badaracco; S Mesiti; M Marugo
Journal:  Horm Res       Date:  1995

5.  Peripartum maternal and foetal ghrelin, growth hormones, IGFs and insulin interrelations.

Authors:  Jens Fuglsang; Puk Sandager; Niels Møller; Sanne Fisker; Jan Frystyk; Per Ovesen
Journal:  Clin Endocrinol (Oxf)       Date:  2006-05       Impact factor: 3.478

6.  Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II.

Authors:  J Frystyk; B Dinesen; H Orskov
Journal:  Growth Regul       Date:  1995-12

7.  Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects.

Authors:  M U Goebel; J Baase; V Pithan; M Exton; B Saller; M Schedlowski; V Limmroth
Journal:  Psychoneuroendocrinology       Date:  2002-11       Impact factor: 4.905

8.  A consensus on criteria for cure of acromegaly.

Authors:  A Giustina; P Chanson; M D Bronstein; A Klibanski; S Lamberts; F F Casanueva; P Trainer; E Ghigo; K Ho; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

9.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

Authors:  A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis.

Authors:  Sharah Hosback; Orla Hardiman; Catherine M Nolan; Maria A C Doyle; Grainne Gorman; Catherine Lynch; Orna O'Toole; Philip Jakeman
Journal:  Growth Horm IGF Res       Date:  2007-08-13       Impact factor: 2.372

View more
  1 in total

Review 1.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.